Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cenicriviroc Mesylate is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2 with anti-inflammatory and antiinfective activity.
ターゲット&IC50 | CCR5:0.29 nM, CCR2:5.9 nM, R5 HIV-1:0.024-0.08 nM (in PBMCs), R5 HIV-2:0.03-0.98 nM (in PBMCs) |
In vivo | Treatment with Cenicriviroc Mesylate results in a dose-dependent reduction in monocyte/macrophage recruitment, reaching statistical significance at dosages of 20 mg/kg/day or higher. When compared to the vehicle-control group, Cenicriviroc Mesylate administration at dosages of 5 mg twice daily (BID), 20 mg BID, 100 mg BID, and 20 mg once daily (QD) leads to decreases in peritoneal lavage monocyte/macrophage counts of 5.7%, 45.2%, 76.5%, and 26.0%, respectively. The effect of Cenicriviroc Mesylate on reducing monocyte/macrophage recruitment is dose-related and demonstrates a correlation with dosage, showing greater efficacy for twice daily (BID) administration compared to once daily (QD). This increased effectiveness is likely due to the higher plasma concentrations achieved with BID dosing and the compound's short half-life of approximately 2 hours in mice [1]. |
別名 | TBR-652 Mesylate, TAK-652 Mesylate |
分子量 | 793.05 |
分子式 | C42H56N4O7S2 |
CAS No. | 497223-28-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (126.10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cenicriviroc Mesylate 497223-28-6 Immunology/Inflammation Microbiology/Virology CCR TBR652 Mesylate TBR-652 Mesylate TAK-652 Mesylate TAK 652 Mesylate TBR 652 Mesylate TAK652 Mesylate Inhibitor inhibitor inhibit